Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer’s disease
Open Access
- 23 July 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Translational Psychiatry
- Vol. 3 (7), e284
- https://doi.org/10.1038/tp.2013.59
Abstract
The β-secretase enzyme BACE1 (β-site amyloid precursor protein-cleaving enzyme 1), which initiates amyloid-β (Aβ) production, is an excellent therapeutic target for Alzheimer’s disease (AD). However, recent evidence raises concern that BACE1-inhibiting approaches may encounter dramatic declines in their abilities to ameliorate AD-like pathology and memory deficits during disease progression. Here, we used BACE1 haploinsufficiency as a therapeutic relevant model to evaluate the efficacy of partial inhibition of this enzyme. Specifically, we crossed BACE1+/− mice with 5XFAD transgenic mice and investigated the mechanisms by which Aβ accumulation and related memory impairments become less sensitive to rescue by BACE1+/− reduction. Haploinsufficiency lowered BACE1 expression by ∼50% in 5XFAD mice regardless of age in concordance with reduction in gene copy number. However, profound Aβ plaque pathology and memory deficits concomitant with BACE1 equivalent to wild-type control levels remained in BACE1+/−·5XFAD mice with advanced age (15–18 months old). Therefore, BACE1 haploinsufficiency is not sufficient to block the elevation of BACE1 expression (approximately twofold), which is also reported to occur during human AD progression, in 5XFAD mice. Our investigation revealed that PERK (PKR-endoplasmic reticulum-related kinase)-dependent activation of eIF2α (eukaryotic translation initiation factor-2α) accounts for the persistent BACE1 upregulation in BACE1+/−·5XFAD mouse brains at 15–18 months of age. Moreover, BACE1 haploinsufficiency was also no longer able to prevent reduction in the expression of neprilysin, a crucial Aβ-degrading enzyme, in 5XFAD mice with advanced age. These findings demonstrate that partial BACE1 suppression cannot attenuate deleterious BACE1-elevating or neprilysin-reducing mechanisms, limiting its capabilities to reduce cerebral Aβ accumulation and rescue memory defects during the course of AD development.Keywords
This publication has 64 references indexed in Scilit:
- β‐Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigmentEMBO Molecular Medicine, 2012
- Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic miceNeurobiology of Disease, 2012
- β‐Secretase inhibitor GRL‐8234 rescues age‐related cognitive decline in APP transgenic miceThe FASEB Journal, 2010
- The secretases: enzymes with therapeutic potential in Alzheimer diseaseNature Reviews Neurology, 2010
- β‐Secretase‐1 elevation in transgenic mouse models of Alzheimer’s disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque developmentEuropean Journal of Neuroscience, 2009
- Failures to reconsolidate memory in a mouse model of Alzheimer’s diseaseNeurobiology of Learning and Memory, 2009
- Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse modelNeurobiology of Disease, 2009
- Phosphorylation of the Translation Initiation Factor eIF2α Increases BACE1 Levels and Promotes AmyloidogenesisNeuron, 2008
- Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1 -null miceProceedings of the National Academy of Sciences of the United States of America, 2008
- BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic miceNeurobiology of Disease, 2007